Post-earnings recap
Reported
Wed, Feb 25, 2026
EPS actual
$7.70
EPS est.
$6.78
EPS surprise
+13.50%
1-day move
+13.03%
The strong EPS performance indicates that United Therapeutics is managing its costs effectively and generating solid profits. The stock's 13.03% increase reflects investor confidence in the company's ability to sustain its earnings momentum. However, the lack of revenue details and future guidance leaves some uncertainty about the overall growth trajectory.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $7.70 | N/A | +13.50% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to shareholder value. However, no specific guidance was provided for future performance.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value to our shareholders.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—